A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.
NCT00077974
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
106
Enrollment
INDUSTRY
Sponsor class
Conditions
Carcinoma, Renal Cell
Interventions
DRUG:
SU011248
Sponsor
Pfizer